TerminatedEarly Phase 1

Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery

Stopped: the study was suspended due to shortage of the study drug (amicar).

United States8 participantsStarted 2013-01

Plain-language summary

This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ability to sign informed consent * Elective cardiac surgery patients undergoing primary surgery involving circulatory arrest Exclusion Criteria: * Inability to sign informed consent * Baseline hypercoagulable condition as defined in medical record * Coronary disease with untreated lesions or recent coronary stent placement * Severe renal dysfunction (ESRD) as documented in medical record

What they're measuring

degree of fibrinolysis as measured by thromboelastography

Timeframe: Length of cardiac surgery

Trial details

NCT IDNCT01965730

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-06

View on ClinicalTrials.gov More Aortic Disease trials